My ePortfolio Register   

IMPAKT Breast Cancer Conference 2013 /
The future of PI3K/AKT/mTOR inhibitors in breast cancer

2nd - 4th May 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.05.13
Views: 3614
Rating:

Dr Sara Hurvitz - UCLA Santa Monica Hematology Oncology, USA

ecancer reporter Peter Goodwin talks to Dr Sara Hurvitz at IMPAKT 2013 in Brussels.

What does the future hold for PI3K/AKT/mTOR inhibitors in breast cancer?

 

ecancer's filming at IMPAKT has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence